A Randomized, Double-Blind, Placebo Controlled, Sequential Parallel Group, Single and Multiple Ascending Doses (SAD/MAD) Study Following Oral Administration in Healthy Subjects to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HPN-01
This study is a randomized, double-blind, placebo-controlled first-in-human study in which the safety, tolerability, pharmacokinetics and pharmacodynamics of orally administered HPN-01 will be evaluated in healthy subjects
100 Clinical Results associated with Hepanova, Inc.
0 Patents (Medical) associated with Hepanova, Inc.
100 Deals associated with Hepanova, Inc.
100 Translational Medicine associated with Hepanova, Inc.